

Is Azithromycin a New Treatment Option for Acute Varioliform Lichenoid Pityriasis?

I. El Modafar^{1,2*}, M. Aboudourib^{1,2}, O. Hocar^{1,2}, S. Amal^{1,2}

¹Department of Dermatology and Venerology, Mohammed the VI th University Hospital, Morocco

²Bioscience and Health Laboratory, Cadi Ayyad University, FMPM Marrakech, Morocco

DOI: <https://doi.org/10.36347/sjmcr.2025.v13i05.052>

| Received: 21.02.2025 | Accepted: 25.03.2025 | Published: 16.05.2025

*Corresponding author: I. El Modafar

Department of Dermatology and Venerology, Mohammed the VI th University Hospital, Morocco

Abstract

Case Report

Pityriasis lichenoides is a rare inflammatory skin condition with acute (PLEVA) and chronic (PLC) variants. There is no standardized treatment, though antibiotics like erythromycin and tetracycline have shown efficacy. This case report describes an 8-year-old with acute varioliform pityriasis lichenoides successfully treated with azithromycin and an H2 antihistamine. The skin lesions resolved within two weeks, leaving transient hyperpigmentation, with no recurrence after two years. Azithromycin's anti-inflammatory and immunomodulatory properties, combined with favorable pharmacokinetics and tolerability, suggest it as a promising alternative therapy for PLEVA.

Keywords: pityriasis lichenoides, azithromycin, PLEVA, pediatric dermatology, rare skin disease, inflammatory dermatosis.

Copyright © 2025 The Author(s): This is an open-access article distributed under the terms of the Creative Commons Attribution **4.0 International License (CC BY-NC 4.0)** which permits unrestricted use, distribution, and reproduction in any medium for non-commercial use provided the original author and source are credited.

INTRODUCTION

Pityriasis lichenoides is a spectrum of rare inflammatory dermatoses of unknown etiology, composed of chronic pityriasis lichenoides (PLC) and acute varioliform pityriasis lichenoides (PLEVA) as main variants, with intermediate forms [1]. There is no therapeutic consensus for this condition, treatment options are based on case series or case reports and include local corticosteroid therapy, antibiotics and phototherapy. Reported use of antibiotics has been limited to tetracycline and erythromycin. We report the case of acute varioliform pityriasis lichenoides in a child that resolved rapidly under treatment with azithromycin.

CASE REPORT

8-year-old patient with no particular pathological history, in particular no notion of drug intake, who presented for the sudden onset of generalized

pruritic papules, more pronounced on the trunk, evolving in a context of fever at 38°C (Figure 1A, 1B). The histological examination revealed an acanthotic epidermis with moderate to severe spongiosis, vacuolar degeneration of the basal layer, and moderate exocytosis of lymphocytes and intraepidermal erythrocytes. The dermis was edematous, with a predominantly lymphocytic inflammatory infiltrate, accompanied by eosinophils, mainly arranged in a perivascular distribution. The diagnosis of acute varioliform pityriasis lichenoides was retained in view of the clinical and histological appearance. The patient was treated with azithromycin at a dose of 10mg/kg/d for 3 days a week for 4 weeks and an H2 antihistamine. The evolution was characterized by the resolution of inflammatory lesions, leaving behind hyperpigmented macules within two weeks of treatment (Figure 2A, 2B). The hyperpigmentation improved after two months, with no recurrence observed after two years (Figure 3A, 3B).




Figure 1




Figure 2



Figure 3

DISCUSSION

Pityriasis lichenoides (PL) is a rare inflammatory dermatosis that preferentially affects children and young adults, evolving by spontaneously regressive flare-ups on the trunk and limbs. A distinction is made between the acute varioliform and necrotic form, a chronic papulosquamous form and a leucomelanodermic form which can occur immediately or succeed the two previous forms [1]. PLEVA has been confused with other dermatoses, some relatively benign

as chickenpox and others potentially malignant like cutaneous T cell lymphoma [2].

The etiopathogenesis of this condition is not clearly elucidated, several authors have mentioned hypersensitivity to an infectious agent [3], which has led to the use of antibiotics such as erythromycin and tetracyclines, with good results due to their anti-inflammatory properties [4, 5]. Azithromycin as a treatment for pityriasis lichenoides has been reported in 4

publications [6-9], in which all patients with PLEVA or PLC evolved well under treatment without recurrence. The favorable response to azithromycin might be due to its anti-inflammatory and immunomodulatory effects by decreasing levels of cytokines and acute phase reactants. Furthermore, azithromycin has better bioavailability, longer half-life and fewer adverse effects compared to erythromycin [10]. Other treatment options include UVB phototherapy, corticosteroids and immunosuppressive agents such as Methotrexate in refractory or severe cases. The excellent response of this disease to azithromycin, its ease of administration and its good tolerance support its role as an alternative treatment modality for PLEVA. More studies are needed to fully elucidate the benefit of this antibiotic in this enigmatic dermatosis.

REFERENCES

1. Devang G. Patel, George Kihiczak, Robert A. Schwartz, MPH Camila K. Janniger, W. Clark Lambert. Pityriasis lichenoides 2000 January;65(1):17-23.
2. Zheng Y, Jia J, Tian Q, *et al.*, Lymphomatoid papulosis misdiagnosed as pityriasis lichenoides et varioliformis acuta: Two case reports and a literature review. *Exp Ther Med.* 2014;8(6):1927-1933.
3. Weiss LM, Wood GS, Ellisen LW: Clonal T-cell populations in lymphomatoid papulosis: evidence of a lymphoproliferative origin for a clinically benign disease. *N Eng J Med* 315: 475-480, 1986.
4. Truhan AP, Hebert AA, Esterly NB. Pityriasis lichenoides in children: therapeutic response to erythromycin. *J Am Acad Dermatol.* 1986 Jul;15(1):66-70.
5. Shelley WB, Griffith RF. Pityriasis lichenoides varioliformis acuta. A Report of a Case Controlled by a High Dosage of Tetracycline. *Arch Dermatol* 1969;100:596-7.
6. Skinner RB, Levy AL. Rapid resolution of pityriasis lichenoides varioliformis acuta with azithromycin. *J Am Acad Dermatol.* 2008;58: 524-525.
7. Ogrum A, Takci Z, Seckin HY, Cetin E. A case of pityriasis lichenoides: Rapid resolution with azithromycin monotherapy in 3 weeks. *Dermatol Ther.* 2018;31:e1268.
8. Di Costanzo L, Balato N, La Bella S, Balato A. Successful association in the treatment of pityriasis lichenoides et varioliformis acuta. *J Eur Acad Dermatol Venereol.* 2009;23:971-972.
9. Feola H, Mancinelli MC, Perez-Klala MV, Vereia MA. Pityriasis lichenoides chronica: Rapid response after a single cycle of azithromycin therapy. *Dermatol Ther.* 2020 May;33(3):e13303.
10. Foulds G, Shepard RM, Johnson RB. The pharmacokinetics of azithromycin in human serum et and tissues. *J Antimicrobial Chemotherapy* 1990;25(suppl A):73- 82.